About Lysogene
Lysogene is a company based in Neuilly-sur-seine (France) founded in 2009. Lysogene has raised $22.61 million across 2 funding rounds from investors including Sarepta Therapeutics, Orbimed and Bpifrance. Lysogene operates in a competitive market with competitors including Spark Therapeutics, Generation Bio, AskBio, Unity Biotechnology and StrideBio, among others.
- Headquarter Neuilly-sur-seine, France
- Stage Public
- SectorsHealthcare
- Website lysogene.com
- Social LinkedIn X
- Total Equity Funding$22.61M (USD)
in 2 rounds
- Latest Funding Round$8.42M (USD), Post-IPO
Mar 2020
- InvestorsSarepta Therapeutics
& 4 more
Funding Insights of Lysogene
Lysogene has successfully raised a total of $22.61M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.42 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.61M
- Total Rounds 2
- Last Round Post-IPO — $8.42M
- First Round $22.61M
(May 2014)
- Investors Count 5
All 2 funding rounds of Lysogene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $8.42M | Post-IPO | – | – | |
| May 2014 | $22.61M | Series A | – | Sofinnova Partners |
5 investors in total: 5 institutional.
Investors in Lysogene
Lysogene has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Sarepta Therapeutics, Orbimed and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
RNA-targeted therapeutics are developed for rare and infectious diseases. | 1980 | sarepta.com | Cambridge, United States | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France |
Investor details for Lysogene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lysogene
4 dated milestones of Lysogene across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Lysogene is founded.
- Funding First funding round of $22.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $8.4M.
Competitors of Lysogene
Lysogene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Generation Bio, AskBio, Unity Biotechnology and StrideBio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| generationbio.com | 2016 | Cambridge, United States | $236.47M | 155 | Gene therapies for rare liver and eye diseases are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. | |
| aviadobio.com | 2019 | London, United Kingdom | $80M | 38 | Developer of gene therapies for neurodegenerative disorders | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. |
Detailed competitors of Lysogene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lysogene
Websites that share an audience with Lysogene (lysogene.com).
Websites whose visitors overlap most with Lysogene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
kinexpharma.com | kinexpharma.com | 100% | – | – | – |
| regenxbio.com | 99% | 19.6K | #1,503,859 | View details | |
| vect-horus.com | 98% | – | – | View details | |
alexionpharma.com | alexionpharma.com | 98% | – | – | – |
alxn.com | alxn.com | 98% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Lysogene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Lysogene
Complete news archive for Lysogene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Lysogene
10 companies that operate in the same segment as Lysogene (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lysogene
Lysogene was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Lysogene is headquartered in Neuilly-sur-seine, France. It is registered at Neuilly-sur-seine, Ile-de-france, France.
Lysogene is a funded company, having raised a total of $22.61M across 2 funding rounds to date. The company's 1st funding round was a Series A of $22.61M, raised on May 2014.
Lysogene was founded in 2009 as a biotechnology firm focused on gene therapy development. Treatments targeting inherited neurodegenerative lysosomal storage disorders, such as mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), are advanced through adeno-associated virus vectors. The lead candidate, LYS-SAF302, incorporates human N-sulfo glucosamine sulfo hydrolase and has undergone Phase III clinical studies. Additional efforts address GM1 gangliosidosis with AAV-based approaches. Operations center on rare disease therapeutics.
Lysogene's top competitors include Spark Therapeutics, Generation Bio and AskBio.
Lysogene has 5 investors. Key investors include Sarepta Therapeutics, Orbimed, Bpifrance, Novo Holdings, and Sofinnova Partners.